Thank you for your interest in CONCERTA[®] (methylphenidate hydrochloride). The following information is provided because of your specific unsolicited request and is not intended as an endorsement of any usage not contained in the Product Monograph.

For complete information, please refer to the CONCERTA[®] Product Monograph, available at <u>http://www.janssen.com/canada/products</u>. For additional information, please see the full scientific summary accompanying these materials.



Literature Summary

- The following summarized literature details CONCERTA[®] (OROS[®] MPH) compared with Teva-methylphenidate ER-C [MPH ER-C[®]], formerly Novo-methylphenidate ER-C
- A literature search did not identify any publications specific to OROS[®] MPH compared with Act-Methylphenidate ER, Apo-Methylphenidate ER and pms-methylphenidate ER

	Study	Design	Outcome Measure	Slides
1	Park-Wyllie 2017	Retrospective Analysis AE Database	Rates Therapeutic Failure	3 - 7
2	Park-Wyllie 2016	Retrospective Cohort Study: IMS Data	Persistence, Duration & Switch	8 - 15
3	Fallu 2016	Randomized Phase IV Study – Adult	Patient Satisfaction	16 - 19
4	Van Stralen 2013	Retrospective Chart Review – Pediatric	Rates Destabilization	20 - 24



Differences in Reported Rates of Therapeutic Failure Between Two Extended-release Methylphenidate Medications

Park-Wyllie L, et al. Clin Ther. 2017; 39(10):2006-23.

Clinical Therapeutics/Volume 39, Number 10, 2017

Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases

Laura Park-Wyllie, PharmD, PhD¹; Judy van Stralen, MD, FRCPC²; Genaro Castillon, MD³; Stephen E. Sherman, PhD¹; and Doron Almagor, MD, FRCPC⁴

¹Janssen Inc, Toronto, Ontario, Canada; ²Center for Pediatric Excellence, Ottawa, Ontario, Canada; ³Université de Montréal, Montréal, Québec, Canada; and ⁴Possibilities Clinic, Toronto, Ontario, Canada

ABSTRACT

Purpose: Our study evaluated adverse events of therapeutic failure (and specifically reduced duration of action) with the use of a branded product, Osmotic Release Oral System (IROS) methylphenidate, which is approved for the treatment of attention deficit/ hyperatextivity disorder, and a generic product (methylphenidate, methylphenidate. RE Re-C), which was approved for marketing in Canada based on bioequivalence to OROS methylphenidate. This study was initiated following reports that some US-marketed generic methylphenidate RE products had substantially higher reporting rates of therapeutic failure than did the referenced brands.

Methods: Through methodology similar to that used by the US Food and Drug Administration to investigate the issue with the US-marketed generic, reporting rates were calculated from cases of therapeutic failure identified in the Canadian Vigilance Adverse Reaction Online database for a 1-year period beginning 8 months after each product launch. Corresponding population exposure was estimated from the number of tablets dispensed. An in-depth analysis of narratives of individual case safety reports (ICSRs) with the use of the generic product was conducted in duplicate by 2 physicians to assess causality and to characterize the potential safety risk and clinical pattern of therapeutic failure. Similar secondary analyses were conducted on the US-marketed products. Findings: Reporting rates of therapeutic failure with the use of methylphenidate ER-C (generic) and OROS methylphenidate (brand name) were 411.5 and 37.5 rate ratio, 10.99; 95% CJ, 533-22.21). In-depth analpsis of narratives of 230 ICSRs of therapeutic failure with the Canadian-marketed generic determined that all ICSRs were either probably (60 [26%)] or possibly (170 [74%]). causally related to methylpheniatre [R-C. Clinical symptoms suggestive of overdose were present in 31 reports of loss of efficacy (13.5%) and occurred primarily in the morning, and premature loss of efficacy (shorter duration of action) was described in 98 cases (12.6%) and occurred primarily in the afternoon. Impacts on social functioning, such as disruption in work or school performance or adverse social behaviors, were found in 51 cases (22.2%). Implications: The -10-fold higher reporting rate of

herapeutic failure with the generic product relative tor its reference product in the present Canadian study resembles findings with US-marketed generic products. While these results should be interpreted with caution due to the limitations of spontaneous adverse event reporting, which may confound comparisons across products, similar findings, nonchicless led the US Food and Drug Administration to declars in 2014 that 2 methylhenidate ER generic products in the United States were neither bioequivalent nor interchangeable with OROS methylhenidate-the generic reference product. Our results indicate a potential safety susse with the Canadian-marketed generic and suggest

yes were conducted on the US-marketed products. Findings: Reporting rates of therapeutic failure with the use of methylphenidate EAC; egrericit and OSO methylphenidate EAC; egrericit and OSO cases per 100000 patienty-years, respectively (reporting cases per 10000 patienty-years, respectively (reporting cases per 10000 patienty-years, respectively (reporting therapeutic patient of the pa

Volume 39 Number 10

Click to open article



	_
\checkmark	- 1
\checkmark	-1

Retrospective analysis of adverse event data from the Canadian Vigilance Adverse Reaction database to:


- Determine reporting rates of therapeutic failure with CONCERTA[®] (OROS MPH) and methylphenidate ER-C (MPH-ER-C[®]) for a 1-year period beginning 8 months after each product launch.
- 2. Conduct an in-depth review of individual case safety reports for therapeutic failure to evaluate temporal relationships, assess causality and characterize the clinical features and clinical course of the events.

Park-Wyllie L, et al. Clin Ther. 2017; 39(10):2006-23.



Results: Differences in AE Reporting Rates of Therapeutic Failure

Reporting rates of therapeutic failure were 10-fold higher for MPH ER-C[®] versus OROS[®] MPH over the prespecified period.



Results: Analysis of Individual Case Reports – MPH ER-C®

- 230 reports were included in the in-depth review
- Clinical presentation of therapeutic failure
 - 98 of the 230 cases (42.6%) reported lack of effect throughout the day with the majority (63/98) occurring in the afternoon
 - 31 cases (13.5%) suggested excessive methylphenidate exposure with the majority of these events occurring in the morning
 - Occurred within one week of starting treatment in 72% of patients (49/68 cases with information available)
 - Impact on social functioning was reported in 51 cases (22%) of patients

Park-Wyllie L, et al. Clin Ther. 2017; 39(10):2006-23.



Summary


- Pharmacovigilance studies using spontaneous reporting data have known limitations; however, these reporting systems remain an essential source of information for regulatory authorities in identifying evolving safety signals
- The present study found a >10-fold higher reporting rate of therapeutic failure with MPH ER-C[®] relative to OROS[®] MPH.
- Pattern of premature loss of efficacy (shorter duration of treatment action) arising in the afternoon hours with MPH ER-C[®] was identified in 64.3% of the 98 patients who reported therapeutic efficacy not lasting throughout the day.
 - The clinical pattern aligns with differences observed in the pharmacokinetic profiles.
- Adverse impacts on social functioning were reported in >20% of cases of therapeutic failure

Park-Wyllie L, et al. Clin Ther. 2017; 39(10):2006-23.



Medication Persistence, Duration of Treatment, and Treatment-switching Patterns Among Patients Taking Once-daily Methylphenidate Medications.*

Park-Wyllie L, et al. Clin Ther. 2016 Aug; 38(8):1789-802.



Janssen Medical Affairs Medical Information November 2019

* Online open access to this publication is not available.



Objectives & Methods

~	_
~	
~	
~	

Population-based retrospective cohort study examining medication persistence, duration of treatment and treatment switching patterns in patients treated with branded OROS[®] MPH vs MPH ER-C[®]


Persistence	 Patient supply of drug at 12 months regardless of gap periods in adherence
Duration of Therapy	 Number of days from first to end of days' supply of last prescription
Treatment Switching	 Patients that were no longer persistent within the first 12 months and subsequently switched to another ADHD medication within 90 days.

Park-Wyllie L, et al. Clin Ther. 2016 Aug; 38(8):1789-802.



Study Results: Identification of Patient Cohorts


Two cohort populations of patients were established using the IMS Brogan insurance claims database focused on Ontario and Québec.



Park-Wyllie L, et al. Clin Ther. 2016 Aug; 38(8):1789-802.

janssen 丁

Study Results: Persistence & Duration of Treatment




Janssen Medical Affairs Medical Information November 2019

Park-Wyllie L, et al. Clin Ther. 2016 Aug; 38(8):1789-802.

Janssen 🔽 🗉

Study Results: Persistence & Duration of Treatment




Janssen Medical Affairs Medical Information November 2019

Park-Wyllie L, et al. Clin Ther. 2016 Aug; 38(8):1789-802.

janssen 丁

Study Results: Treatment Switching Patterns




Janssen Medical Affairs Medical Information November 2019

Park-Wyllie L, et al. Clin Ther. 2016 Aug; 38(8):1789-802.

Janssen

Study Results: Treatment Switching Patterns



Janssen Medical Affairs Medical Information November 2019

Park-Wyllie L, et al. Clin Ther. 2016 Aug; 38(8):1789-802.

janssen 🗍

Summary

- Significant differences were observed in how OROS[®] MPH & MPH ER-C were used by patients in the real-world setting
 - In the OROS[®] MPH experienced cohort, OROS[®] MPH was associated with a 70% higher rate of medication persistence at 12 months relative to MPH ER-C[®] (adjusted relative risk [ARR] = 1.70; 95% CI, 1.64-1.77)
 - In the new-user cohort, OROS[®] MPH had a 58% higher rate of medication persistence relative to MPH ER-C[®] (ARR = 1.58; 95% CI, 1.51-1.65)
 - Median duration of therapy was significantly longer (P < 0.0001) in patients taking OROS[®] MPH compared with those taking MPH ER-C[®]
 - Treatment-switching occurred significantly (P < 0.0001) more frequently in patients taking MPH ER-C[®] compared with those taking OROS[®] MPH



A Randomized, Double-Blind, Cross-Over, Phase IV Trial of OROS[®]-MPH and Generic MPH ER-C[®]

Fallu A, et al. Ther Adv Psychopharmacol. 2016 Aug; 6(4):237-51.

A randomized, double-l	olind. cross-over.	Ther Adv Psychophar 2016, Vol. 6(6) 237-3
phase IV trial of oros-m		2016, Vol. 6(4) 237-21 DOI: 10.1177/ 2045125316663676
(CONCERTA®) and gene		© The Author(s), 201 Reprints and permiss
novo-methylphenidate		http://www.sagepub.c journatsPermissions.
Angelo Fallu, Farida Dabouz, Melissa Furtado, L	eena Anand and Martin A. Katzman	
Abstract: Objective: Attention-deficit/hyperactivity disord	der (ADHD) is a common neurobebavioral	
disorder with onset during childhood. Multiple		
hindered, in both home and school settings, wi		
cognitive functioning. If left untreated, ADHD is achievement and low occupational status, as w		
and delinquency. The objective of this study wa	s to evaluate adult ADHD subject reported	
outcomes when switched from a stable dose of Novo-methylphenidate ER-C®.	f CONCERTA® to the same dose of generic	
Methods: Randomized, double-blind, cross-ov	er, phase IV trial consisted of two phases in	
	ADHD were randomized in a 1:1 ratio to 3 weeks	
of treatment with CONCERTA or generic Novo- treatment, participants were crossed-over to r		
3 weeks. Primary efficacy was assessed through		
Questionnaire for Medication, Version II (TSQM		Correspondence to:
Results: Participants with ADHD treated with 0 efficacy and side effects compared to those res		Angelo Fallu, MD, FRC Clinique Woodward, 71
Methylphenidate ER-C. All participants chose t		rue Woodward, DIEX Research Inc., Sherbro DC, J10 1W6, Canada
conclusion of the study.	Novo-Methylphenidate ER-C have been deemed	cliniqueweodward@ videotron.ca
	monstrate clinically and statistically significant	Farida Dabouz, PhD FB2D Clinical Research
differences between generic and branded CON	CERTA. Further investigation of these	Consulting, Montréal, Québec, Canada
differences is warranted.		Melissa Furtado, BSc (Hons)
Keywords: attention-deficit/hyperactivity dis	order, bioequivalence, CONCERTA®, generic,	START Clinic for Mood and Anxiety Disorders,
novo-methylphenidate		Torente, ON, Canada Leena Anand, BA (Hen
to be a dead of the		START Clinic for Mood and Anxiety Disorders,
Introduction Attention-deficit/hyperactivity disorder (ADHD)	et al. 2007]. ADHD represents a significant eco- nomic burden to our society, such that in 2005 in	Toronto, ON, Canada Martin A. Katzman, MI
is a chronic neurobiological disorder, character-	the United States, the cost of the disorder was	FRCPC START Clinic for Mood
ized by behavioral and cognitive deficits [Biederman et al. 2009; Westerberg et al. 2010;	approximately US\$36–52 billion [Pelham et al. 2007]. Furthermore, ADHD results in an esti-	and Anxiety Disorders, Toronto, ON, Canada
Pazvantoglu et al. 2012] associated with signifi-	mated loss of 143.8 million days of work produc-	The Northern Ontario School of Medicine, Thunder Bay, ON, Cana
cant impairment in psychological, occupational and social functioning in adults [Biederman et al.	tivity annually [de Graaf et al. 2008].	Thunder Bay, DN, Cana Department of Psychol Lakehead University.
2005, 2006; Kessler et al. 2006]. The literature		Thunder Bay, ON, Cana University of Toronto.
has estimated prevalence rates of 5.3% in chil- dren and adolescents [Polanczyk et al. 2007], and	under diagnosed among adults [Faraone, 2004]. In part, the diagnosis of adult ADHD remains	Torente, ON, Canada Adler Graduate
3.4-4.4% in adults [Kessler et al. 2006; Fayyad		Professional School, Torente ON, Canada






Objective & Methods

l	\checkmark	_
l	\checkmark	_
l	\checkmark	_
	\checkmark	_

A single centre, randomized, double-blind, crossover Phase IV study with no washout, evaluating adult ADHD patient satisfaction when switched from a stable dose of OROS[®]-MPH to the same dose of the generic MPH-ER-C[®]



Janssen Medical Affairs Medical Information November 2019

Fallu A, et al. Ther Adv Psychopharmacol. 2016 Aug; 6(4):237-51.

Jansser

Study Results: Primary Efficacy Endpoint

Randomization Group Change from Screening		OROS®MPH (n=17)	MPH ER-C® (n=19)	p-value (between treatments)
TSQM-II	p-value	No Change	Significantly decreased	0.0433
Effectiveness	(vs screening)	0.5852 (NS)	0.0037	0.0433
TSMQ-II Side Effects	p-value (vs screening)	No Change	Significantly increased	0.0321
		0.1252 (NS)	0.0001	
TSMQ-II Global Satisfaction	p-value (vs screening)	No Change 0.1015 (NS)	Significantly decreased 0.0004	0.0791 (NS)

TSMQ II : Treatment Satisfaction Questionnaire for Medication, version II

Janssen Medical Affairs Medical Information November 2019

Fallu A, et al. Ther Adv Psychopharmacol. 2016 Aug; 6(4):237-51.



Study Conclusions

- This study showed clinically and statistically significant differences between the MPH-ER-C[®] and OROS[®] MPH treatments in both subject- and physician-reported treatment outcomes as well as in subject discontinuation rates
 - Adults treated with a stable dose of OROS[®]-MPH were more satisfied, as per the Treatment Satisfaction Questionnaire for Medication (TSQM-II) in terms of efficacy and side effects than those receiving an equivalent dose of the MPH-ER-C[®]
 - All subjects elected to return to OROS[®]-MPH at the conclusion of the trial
 - The authors note that the number of subjects is also too small to draw definitive conclusions and a larger head-to-head trial is needed to confirm this trend



Clinical impact of switching patients from OROS[®]-MPH to MPH ER-C[®]: A pediatric practice review

van Stralen JP. Paediatr Child Health. 2013 Feb;18(2):70-3.

Click to open article

Janssen Medical Affairs Medical Information November 2019




	_
~	_
~	_
\checkmark	_

Retrospective, observational, chart review of consecutive ADHD patients (aged 5-18 years) from a single pediatric practice who were prescribed OROS[®] MPH from May 1 to November 27, 2010 to determine the clinical impact of switching to MPH ER-C[®].

Primary Outcome	 Proportion of patients destabilized Destabilization: change in symptoms and/or function resulting from a ADHD medication or dosage change
Secondary Outcome	 Qualitative assessment of the effects of the switch



Study Results: Primary Efficacy Endpoint



Janssen Medical Affairs Medical Information November 2019

van Stralen JP. Paediatr Child Health. 2013 Feb;18(2):70-3.

janssen 🗍

Study Results: Secondary Efficacy Endpoints

Secondary endpoints were reported by the study author in a qualitative manner without incidence rates nor statistical significance.

Efficacy	 MPH ER-C[®] appeared to be less effective than OROS[®]-MPH: Comments: "feels like not taking the medication at all" the patient was "completely destabilized" and "bouncing off the walls"
Adverse Events	Different side effects while treated with MPH ER-C [®] : • Dizziness, eating more, not sleeping well and anger.
Duration of Action	 MPH ER-C[®] was reported to have a shorter duration of action vs OROS[®]-MPH: Patients/parents reported 7 or 8 h of effect and some patients required an additional dose of immediate release MPH.

van Stralen JP. Paediatr Child Health. 2013 Feb;18(2):70-3.



- 87% of patients who were switched from OROS[®]-MPH to MPH ER-C[®] clinically destabilized, corresponding to a 66% increase in destabilization compared with those who were left on OROS[®]-MPH
- Qualitative reports indicated inferior tolerability, lower effectiveness and a shorter duration of action with MPH ER-C[®]



Summary

Cloud Thequetty Vol	and M. Samler 10, 1971	Revenue A
Differences in Adverse Event F Therapeutic Failure Berwen T Extended-release Methylphenic Canada: Analysis of Spontance Reporting Databases Law Park Wile, Parel D. Po ¹ , Judy on Genet Cathon, M ² , Report F. Bones	I'wo Once-daily late Medications in ous Adverse Event	A rando phase IV (CONCE novo-mo
Januari Ini, Fanatsi, Ostaria, Colasti: ² Conter J Mineretti de Mastelet, Mantelet, Qarker, Canad	ir Palistic Euriffees, Clares, Ortons, Ganala; is and "Produkter Clare, Toroba, Oktava, Ganala	Aberry .
<text><text><text></text></text></text>	The sector of th	 Dividente veri veri di città di cit
-	Taken 12 South 12	5 8 4 474 to all

domized, double-blind, cross-over, e IV trial of oros-methylphenidate CERTA®) and generic methylphenidate ER-C (NOVO-generic)

Medication Periotence, Duration of Treatment, and Treatment-wisching Patterns Anong Canadian Pattern Taking Doue-daily Extended-release Methylphenidate Medications for Attention-Dehick/Hyperactinity Disorder: A Dipulation-based Retrospective Cohort Study Territ Antonio Sci Million and Statistical Sci Antonio Million and Antonio Million and Antonio Antonio Sci Antonio Ant

Interest Int. Namedian & 1912

The clinical impact of switching attention deficit hyperactivity disorder patients from OROS®.MPH to Novo-MPH ER-C®: A paediatric practice review Venice. The chiefd leaver of weights process prepared alongly prime loss UROP 10781 or 10:12127-13 products product writes Technol.

Janssen Medical Affairs Medical Information November 2019



Clinical Summary Conclusions


Study	Design	Slides
Park Wyllie 2017 Retrospective Analysis	Canada Vigilance Adverse Reaction Database analysis: 10-fold higher reporting rate of therapeutic failure for MPH ER-C [®] vs. OROS [®] MPH over 1-year period.	3 - 7
Park Wyllie 2016 Retrospective Cohort Study	Patients taking OROS [®] MPH remained on treatment for significantly longer and were less likely to become non-persistent over 12-month period vs. MPH ER-C [®]	8 - 15
Fallu 2016 Adult Randomized, Double-Blind, Crossover Study	Greater satisfaction with efficacy & side effects on OROS [®] MPH vs. MPH ER-C [®] . All participants chose to continue with OROS [®] MPH treatment at study conclusion	16 - 19
<u>Van Stralen 2013</u> Pediatric Retrospective Chart Review	87% destabilized for those switched from OROS [®] MPH to MPH ER-C [®] vs. 26% who remained on OROS [®] MPH. Of the destabilized patients who switched to MPH ER-C [®] , 43% reported a shorter duration of effect.	20 - 24

Janssen Medical Affairs Medical Information November 2019



Please refer to the full scientific summary for additional summarized literature.

If you have any additional questions please contact Janssen Medical Information



Janssen Medical Affairs Medical Information November 2019

